Peter Szecsödy

590 total citations
6 papers, 88 citations indexed

About

Peter Szecsödy is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Peter Szecsödy has authored 6 papers receiving a total of 88 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Cardiology and Cardiovascular Medicine, 2 papers in Pulmonary and Respiratory Medicine and 1 paper in Surgery. Recurrent topics in Peter Szecsödy's work include Heart Failure Treatment and Management (3 papers), Cardiovascular Function and Risk Factors (2 papers) and Potassium and Related Disorders (2 papers). Peter Szecsödy is often cited by papers focused on Heart Failure Treatment and Management (3 papers), Cardiovascular Function and Risk Factors (2 papers) and Potassium and Related Disorders (2 papers). Peter Szecsödy collaborates with scholars based in Switzerland, United Kingdom and United States. Peter Szecsödy's co-authors include Ghionul Ibram, Burkert Pieske, Jianjian Gong, Rolf Wachter, Sanjiv J. Shah, Victor Shi, Martín Cowie, Sven Klebs, Adisak Tantiworawit and Marco Metra and has published in prestigious journals such as American Heart Journal, European Journal of Heart Failure and ESC Heart Failure.

In The Last Decade

Peter Szecsödy

6 papers receiving 85 citations

Peers

Peter Szecsödy

CCM

PRM

EDM

BE

HEMAT

Atsushi Tada Japan

Anna Bobenko Germany

Evelyne Meekers Belgium

Mustafa Kürşat Tigen Türkiye

Maria G. Crespo‐Leiro Spain

Michele Senni Italy

Paula Campora Italy

Stefan Leggewie Germany

Katrien Tartaglia Belgium

Susan Neal United States

Atsushi Tada Japan

Peter Szecsödy

100 ×1.5

CCM

8 ×0.2

PRM

23 ×1.4

EDM

4 ×0.4

BE

7 ×0.9

HEMAT

Citations per year, relative to Peter Szecsödy Peter Szecsödy (= 1×) peers Atsushi Tada

Countries citing papers authored by Peter Szecsödy

Since Specialization

Citations

This map shows the geographic impact of Peter Szecsödy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Szecsödy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Szecsödy more than expected).

Fields of papers citing papers by Peter Szecsödy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Szecsödy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Szecsödy. The network helps show where Peter Szecsödy may publish in the future.

Co-authorship network of co-authors of Peter Szecsödy

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Szecsödy. A scholar is included among the top collaborators of Peter Szecsödy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Szecsödy. Peter Szecsödy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Taher, Alì, et al.. (2022). S272: SAFETY AND PRELIMINARY PHARMACODYNAMIC EFFECTS OF THE FERROPORTIN INHIBITOR VAMIFEPORT (VIT-2763) IN PATIENTS WITH NON-TRANSFUSION-DEPENDENT BETA THALASSEMIA (NTDT): RESULTS FROM A PHASE 2A STUDY. HemaSphere. 6. 173–174. 9 indexed citations

2.

Butler, Javed, Stefan D. Anker, Tariq Jamal Siddiqi, et al.. (2021). Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. European Journal of Heart Failure. 24(1). 230–238. 26 indexed citations

3.

Shah, Sanjiv J., Martín Cowie, Rolf Wachter, et al.. (2021). Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction. European Journal of Heart Failure. 23(9). 1541–1551. 13 indexed citations

4.

Wachter, Rolf, Sanjiv J. Shah, Martín Cowie, et al.. (2020). Angiotensin Receptor Neprilysin Inhibition versus Individualized RAAS Blockade: Design and Rationale of the PARALLAX Trial. ESC Heart Failure. 7(3). 856–864. 29 indexed citations

5.

Gimpelewicz, Claudio, Marco Metra, John G.F. Cleland, et al.. (2017). Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. American Heart Journal. 190. 113–122. 10 indexed citations

6.

Szecsödy, Peter, et al.. (2002). [Chest pain unit--viable option when risk of cardiac etiology is modest. Multitudinous patient population brought together for structured survey and care at appropriate level].. PubMed. 99(48). 4848–53. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact